Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vanquis returns to profitability in H1, recovery remains on track

(Sharecast News) - Sub-prime lender Vanquis said on Thursday that its recovery remained firmly on track, with improved credit quality, lower complaint costs, and disciplined cost control all helping it return to profitability. Vanquis posted a statutory pre-tax profit of £6.2m for the six month ended 30 June, bouncing back from the prior year's £46.1m loss, with a 24% drop in operating costs to £137.4m, driven by transformation savings and reduced Financial Ombudsman Service fees and a 36% year-on-year reduction in complaint costs to £16.1m.

Gross customer interest-earning balances rose 7% to £2.46bn, with expectations now set above £2.6bn by year-end, while risk-adjusted income increased 7% to £143.6m, supported by a drop in cost of risk from 8.5% to 6.6%. Statutory return on tangible equity improved to 3.1%, up from -18.9% last year.

On the other hand, net interest income dipped 2% to £202.2m, while total income fell 3% to £219.7m, reflecting higher funding costs.

Vanquis also highlighted that it was not exposed to discretionary commission arrangements, distancing itself from potential liabilities tied to the FCA's proposed motor finance redress scheme.

As of 0955 BST, Vanquis shares had surged 12.13% to 115.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.